Brief: Alpha Cognition Announces Positive Topline Results From Bioequivalence Study With Alpha-1062 In Development For Alzheimer's Disease
22/08/2022 14:06
Aug 22 (Reuters) - Alpha Cognition Inc ACOG.V :
* ALPHA COGNITION ANNOUNCES POSITIVE TOPLINE RESULTS FROM
BIOEQUIVALENCE STUDY WITH ALPHA-1062 IN DEVELOPMENT FOR
ALZHEIMER’S DISEASE
Source text for Eikon: ID:nBw7JVzmZa
Further company coverage: ACOG.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alpha Cognition
See all newsBrief: Alpha Cognition Announces Pricing Of $50 Million Upsized Public Offering And Nasdaq Listing
Brief: Alpha Cognition Inc - Files Registration Statement For $25 Million Offering
Brief: Alpha Cognition Announces Completion Of $4.545 Million Convertible Note And Warrants Bridge Financing
Brief: Alpha Cognition Says On Track To Secure Financing For Continued Growth
Brief: Alpha Cognition Inc Says Applied To List Common Shares On Nasdaq Under Trading Symbol “Acog”